Literature DB >> 28018585

Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men.

Emma O Billington1, Greg D Gamble2, Ian R Reid2.   

Abstract

Hyperparathyroidism may be associated with skeletal and cardiovascular abnormalities, but it is unclear whether these associations exist for high-normal levels of parathyroid hormone (PTH). We assessed relationships between PTH and anthropometric, skeletal and cardiometabolic indices in normal men. Body composition, blood pressure, biochemistry and bone mineral density (BMD) were evaluated in 151 healthy men. BMD was reassessed at 2 years, and coronary artery calcium (CAC) was measured at 3.5 years. Relationships between PTH and other baseline characteristics, CAC scores and change in BMD were evaluated. PTH correlated positively with baseline body mass index, fat mass, diastolic blood pressure, triglycerides, total and low-density lipoprotein (LDL) cholesterol, (r=0.19-0.25, P=0.02-0.002), and with category of CAC score. Relationships between PTH and cardiometabolic indices remained significant after adjustment for age, 25-hydroxyvitamin D and estimated glomerular filteration rate. Men in the top PTH tertile (⩾4.4 pmol l-1, n=51) were more likely to have LDL cholesterol ⩾3.5 mmol l-1, diastolic blood pressure ⩾85 mm Hg, and CAC score >0 than men in lower tertiles. PTH was not associated with history of fracture, baseline BMD, or change in BMD over 2 years. In summary, in this cohort of healthy men, PTH levels are linearly related to adiposity and to cardiometabolic indices, but not to BMD or bone loss. These findings suggest that adiposity should be considered as an independent cause of secondary hyperparathyroidism, and they may be relevant to patients with normocalcemic hyperparathyroidism, in whom high PTH levels may be a marker of adiposity and cardiometabolic risk rather than always indicating parathyroid autonomy.

Entities:  

Year:  2016        PMID: 28018585      PMCID: PMC5141601          DOI: 10.1038/bonekey.2016.85

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN: 2047-6396


  44 in total

1.  Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?

Authors:  Jeffrey L Anderson; Ryan C Vanwoerkom; Benjamin D Horne; Tami L Bair; Heidi T May; Donald L Lappé; Joseph B Muhlestein
Journal:  Am Heart J       Date:  2011-08       Impact factor: 4.749

2.  Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening.

Authors:  Emil Hagström; Ewa Lundgren; Jonas Rastad; Per Hellman
Journal:  Eur J Endocrinol       Date:  2006-07       Impact factor: 6.664

3.  Parathyroid hormone and calcium are independently associated with subclinical vascular disease in a community-based cohort.

Authors:  Emil Hagström; Tommy Ahlström; Johan Ärnlöv; Anders Larsson; Håkan Melhus; Per Hellman; Lars Lind
Journal:  Atherosclerosis       Date:  2014-12-20       Impact factor: 5.162

4.  Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity.

Authors:  Elizabeth Grethen; Kathleen M Hill; RoseMarie Jones; Brenda M Cacucci; Christine E Gupta; Anthony Acton; Robert V Considine; Munro Peacock
Journal:  J Clin Endocrinol Metab       Date:  2012-02-22       Impact factor: 5.958

Review 5.  Normocalcemic primary hyperparathyroidism.

Authors:  Natalie E Cusano; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

6.  Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women.

Authors:  Elizabeth Sienkiewicz; Faidon Magkos; Konstantinos N Aronis; Mary Brinkoetter; John P Chamberland; Sharon Chou; Kalliopi M Arampatzi; Chuanyun Gao; Anastasia Koniaris; Christos S Mantzoros
Journal:  Metabolism       Date:  2011-07-07       Impact factor: 8.694

7.  Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism.

Authors:  Karen M Tordjman; Marianna Yaron; Elena Izkhakov; Etty Osher; Galina Shenkerman; Yonit Marcus-Perlman; Naftali Stern
Journal:  Eur J Endocrinol       Date:  2010-05       Impact factor: 6.664

8.  Hypertension, Antihypertensive Medications, and Risk of Incident Primary Hyperparathyroidism.

Authors:  Anand Vaidya; Gary C Curhan; Julie M Paik; Henry Kronenberg; Eric N Taylor
Journal:  J Clin Endocrinol Metab       Date:  2015-04-17       Impact factor: 5.958

Review 9.  2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.

Authors:  Todd J Anderson; Jean Grégoire; Robert A Hegele; Patrick Couture; G B John Mancini; Ruth McPherson; Gordon A Francis; Paul Poirier; David C Lau; Steven Grover; Jacques Genest; André C Carpentier; Robert Dufour; Milan Gupta; Richard Ward; Lawrence A Leiter; Eva Lonn; Dominic S Ng; Glen J Pearson; Gillian M Yates; James A Stone; Ehud Ur
Journal:  Can J Cardiol       Date:  2013-02       Impact factor: 5.223

10.  Plasma-parathyroid hormone is associated with subclinical and clinical atherosclerotic disease in 2 community-based cohorts.

Authors:  Emil Hagström; Karl Michaëlsson; Håkan Melhus; Thomas Hansen; Håkan Ahlström; Lars Johansson; Erik Ingelsson; Johan Sundström; Lars Lind; Johan Arnlöv
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-03-13       Impact factor: 8.311

View more
  3 in total

1.  An inverted U-shaped relationship between parathyroid hormone and body weight, body mass index, body fat.

Authors:  Tian-Jiao Yuan; Liu-Ping Chen; Ya-Ling Pan; Yong Lu; Li-Hao Sun; Hong-Yan Zhao; Wei-Qing Wang; Bei Tao; Jian-Min Liu
Journal:  Endocrine       Date:  2021-02-06       Impact factor: 3.633

2.  Prevalence, Characteristics, and Associated Risk Factors of Wrist Fractures in Americans Above 50: The Cross-Sectional NHANES Study.

Authors:  Juncai Ye; Qiao Li; Jing Nie
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-25       Impact factor: 6.055

Review 3.  Serum biomarkers for arterial calcification in humans: A systematic review.

Authors:  Nienke M S Golüke; Marit A Schoffelmeer; Annemarieke De Jonghe; Mariëlle H Emmelot-Vonk; Pim A De Jong; Huiberdina L Koek
Journal:  Bone Rep       Date:  2022-06-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.